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ABBREVIATIONS 
 
BiPhP, biphenyl polyphosphate; BzP, benzene polyphosphate; mCPBA, meta-
chloroperbenzoic acid; diC8-PtdIns(4)P, diC8-PtdIns(4)P,  HEPES, 2-[4-(2-
hydroxyethyl)piperazin-1-yl) ethanesulfonic acid; IMAC, Immobilized Metal Affinity 
Chromatography; INPP5A, type I inositol 5-phosphatase; INPP5B, type II inositol 5-
phosphatase; Ins(1,4)P2 myo-inositol 1,4-bisphosphate; Ins(1,4,5)P3 myo-inositol 1,4,5-
trisphosphate; Ins(1,3,4,5)P4 myo-inositol 1,3,4,5-tetrakisphosphate OCRL-1, Lowe 
oculocerebrorenal syndrome protein (INPP5F); PH-domain Pleckstrin Homology 
domain; PKBα, Protein kinase Bα; PtdIns(3,4,5)P3, Phosphatidyinositol 3,4,5-
trisphosphate; SHIP1, SH2-domain containing Inositol 5-phosphatase type 1; SHIP2, 
SH2-domain containing Inositol 5-phosphatase, type 2; TEAB, triethylammonium 
bicarbonate; TCA, trichloroacetic acid; TCEP, (tris(2-carboxethyl)phosphine); 
TMSBr, bromotrimethylsilane. 
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ABSTRACT 
 
The inositol polyphosphate 5-phosphatase INPP5B hydrolyzes the 5-phosphate group 
from water- and lipid-soluble signaling messengers. Two synthetic benzene and 
biphenyl polyphosphates (BzP/BiPhPs), simplified surrogates of inositol phosphates 
and phospholipid headgroups, were identified by thermodynamic studies as potent 
INPP5B ligands. The X-ray structure of the complex between INPP5B and biphenyl 
3,3,4,4,5,5-hexakisphosphate [BiPh(3,3,4,4,5,5)P6, IC50 5.5 µM] was determined at 
2.89Å resolution. One inhibitor pole locates in the phospholipid headgroup binding site 
and the second solvent-exposed ring binds to the His-Tag of another INPP5B molecule, 
while a molecule of inorganic phosphate is also present in the active site. Benzene 1,2,3-
trisphosphate [Bz(1,2,3)P3] [one ring of BiPh(3,3,4,4,5,5)P6] inhibits INPP5B ca 6-
fold less potently. Co-crystallization with benzene 1,2,4,5-tetrakisphosphate 
[Bz(1,2,4,5)P4, IC50 = 6.3 µM] yielded a structure refined at 2.9Å resolution. Conserved 
residues among the 5-phosphatase family mediate similar interactions with 
Bz(1,2,4,5)P4 and BiPh(3,3',4,4',5,5')P6 to those with the polar groups present in 
positions 1,4,5 and 6 on the inositol ring of the substrate. 5-Phosphatase specificity most 
likely resides in the variable zone located close to the 2- and 3-positions of the inositol 
ring. We propose that the inorganic phosphate present in the 
INPP5BBiPh(3,3,4,4,5,5)P6 complex mimics the post-cleavage substrate 5-
phosphate released by INPP5B in the catalytic site, allowing elucidation of two new 
key features in the catalytic mechanism proposed for the family of phosphoinositide 5-
phosphatases: first, the involvement of the conserved Arg-451 in the interaction with 
the 5-phosphate and secondly, identification of the water molecule that initiates 5-
 4 
phosphate hydrolysis. Our model also has implications for the proposed moving metal 
mechanism. 
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There are ten human Mg2+-dependent inositol 5-phosphatase isoenzymes that cleave 
the 5-phosphate of some inositol phosphates and inositol phospholipid derivatives. 
Only type I inositol 5-phosphatase (INPP5A) is specific for inositol phosphates, the 
remaining nine enzymes can hydrolyze either inositol phospholipids or both inositol 
phospholipids and inositol phosphates [1]. 
 
Some inositol 5-phosphatases are implicated in disorders including cancer, diabetes, 
obesity and neurodegenerative diseases [1,2]. Four 5-phosphatase crystal structures 
with bound ligands are known, namely INPP5B in complex either with diC8PtdIns(4)P 
or diC8PtdIns(3,4)P2 (PDB, 3MTC and 4CML, respectively), the polyphosphate 5-
phosphatase domain of SPsynaptojanin (PDB, 1I9Z) (from yeast Schizosaccharomyces 
pombe hence SPsynaptojanin) in complex with Ins(1,4)P2 [3] and a SHIP2–
BiPh(2,3',4,5',6)P5 complex (PDB, 4A9C) [4]. The closest structural family member of 
INPP5B is OCRL-1 (INPP5F), also known as Lowe oculocerebrorenal syndrome 
protein and is associated with the rare X-linked human genetic disorder [5]. In the 
structure of OCRL (PDB, 4CMN) [6], an inorganic phosphate molecule was identified 
in the active site and suggested to mimic either the 5-phosphate of the substrate or the 
scissile phosphate obtained after its hydrolysis. The coordinates of another inositol 5-
phosphatase, the phospholipid-specific INPP5E (PDB, 2XSW), in its apo-form, are also 
available in the PDB [7]. 
 
Type II inositol 5-phosphatase (INPP5B) is a 5-phosphatase that hydrolyzes both 
inositol phosphates and inositol phospholipids [8]. INPP5B was first identified in 
platelets [9] and has similar affinities for both PtdIns(4,5)P2 and Ins(1,4,5)P3 [10]. 
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INPP5B plays a role in the endocytic pathway [11] and the early secretory pathways 
[12], binding to the small GTPase protein Rab5 (that also binds OCRL). The gram 
negative bacterium, Yersinia pseudotuberculosis causes Far East scarlet-like fever in 
humans. The organism invades host cells in a process similar to phagocytosis [13], 
hijacks INPP5B and OCRL which are then recruited to hydrolyze phosphatidylinositol 
4,5-bisphosphate [PtdIns(4,5)P2] from the host organism. Enzymatic hydrolysis of 
PtdIns(4,5)P2 together with the association of the GTPase Rab5 with prevacuoles 
completes the multistep invasion process [13]. INPP5B and OCRL may be potential 
targets for inhibition by specific 5-phosphatase ligands. However, to date there is no 
specific human disease associated with INPP5B. 
 
Due to the therapeutic importance of these enzymes, attempts to identify lead ligands 
for drug-discovery have been initiated. A high throughput screening methodology for 
small molecule inhibitors of inositol 5-phosphatase enzymes was recently developed 
by the De Camilli group [14]. Compound YU142670 (1, Figure 1) was identified as an 
inhibitor of two enzymes INPP5B (IC50 = 1.78 µM) and OCRL (IC50 = 0.71 µM). 
YU142670 became the lead compound for evaluating binding by isothermal titration 
calorimetry and several other assays, providing a platform for development of new 
specific and potent inhibitors. 
 
Several methods are currently available for characterizing protein binding partners 
without monitoring enzyme activity [15,16]. One such method developed by the 
Structural Genomics Consortium (SGC) [15] uses light scattering-based approaches to 
measure the variation of the thermal stability of proteins (thermal-shift) when screened 
against a library of compounds. The principle of this light scattering-based approach is 
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that ligand binding stabilizes a protein structure to thermal unfolding and subsequent 
aggregation. Thus, the temperature at which the protein begins to aggregate, where light 
scattering is dramatically enhanced, increases in the presence of ligand. Those ligands 
which provide the highest temperature increase under optimum conditions are good 
candidates for X-ray crystal structure studies. The ligands that were selected were from 
the benzene and biphenyl phosphate class. 
 
Previously, we demonstrated the potential of benzene- and biphenyl phosphates as 
inositol phosphate surrogates for structural studies [4,17]. Benzene 1,2,3,4-
tetrakisphosphate Bz(1,2,3,4)P4, co-crystallized with the pleckstrin homology (PH) 
domain of protein kinase Bα (PKBα) [17] and is a good surrogate for the 
phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3] headgroup, inositol 1,3,4,5-
tetrakisphosphate, Ins(1,3,4,5)P4 (2, Figure 1). These studies led by others, generated 
drug-like inhibitors of the PKB PH domain by virtual screening [18]. We have also co-
crystallized SHIP2 in complex with biphenyl 2,3,4,5,6-pentakisphosphate, 
BiPh(2,3,4,5,6)P5; the resulting structure facilitated identification of a mobile loop 
located above the binding site [4]. Synthetic benzene- and biphenyl phosphates 
(BzPs/BiPhPs) are compounds that could be used generically in the early stages of 
structure-based drug design targeting phosphoinositide-related pathways. 
 
 
Figure 1 here 
 
Here we present the results of the thermal-shift screen that we used to select candidates 
from forty ligands when assayed against eight of the ten catalytic domains of inositol 
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phosphate 5-phosphatases. We report crystal structures for two INPP5B 5-phosphatase 
domain–ligand complexes formed in the presence of small molecule benzene phosphate 
(BzP and BiPhP) inhibitors that emerged from screening. First, INPP5B and biphenyl 
3,3,4,4,5,5-hexakisphosphate, BiPh(3,3,4,4,5,5)P6 (3, Figure 1), and second, 
INPP5B in complex with benzene 1,2,4,5-tetrakisphosphate, Bz(1,2,4,5)P4 (4, Figure 
1). The results further extend the potential of the BzP/BiPhP substrate surrogate 
approach, allowing us to identify the region of the inhibitors that is important to 
modulate their selectivity towards specific 5-phosphatase members and to offer new 
insights into the mechanism of INPP5B-catalyzed phosphate group cleavage (see 
Supporting Information Scheme S1, Table S1 and Figure S1A-S1C). 
 
EXPERIMENTAL 
 
The general methods were followed according to a previous report [19] and the 
synthesis was performed according to Scheme 1. 
 
3,3,4,4,5,5-Hexamethoxybiphenyl (7). A mixture of K2CO3 (1.11 g, 8 mmol), 
Pd(OAc)2 (4 mg, 0.5%), 1,2,3-trimethoxy-5-bromobenzene (5) (988 mg, 4 mmol) and 
3,4,5-trimethoxyphenylboronic acid (6) (1.27 g, 6 mmol), and in distilled water (15 mL) 
and acetone (12 mL) was stirred for 1 h at 35 ºC. The reaction mixture was partitioned 
between water and CH2Cl2 (50 mL of each) and the remaining solid was purified by 
flash chromatography (CH2Cl2 alone and was pure enough without recrystallization. 
Yield (902 mg, 67%). Rf in CH2Cl2-ether (10:1) = 0.35; m.p. = 129–130 ºC (Lit. [20], 
129–130 ºC). 1H NMR (400 MHz, CDCl3) 3.89 (s, 6 H, 2  ArOMe), 3.93 (2 s, 12 H, 4 
 ArOMe), 13C NMR (100 MHz, CDCl3) 56.24, (t, 4  ArOMe), 104.58 (d, 4  ArH), 
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137.54, 137.67 (2 d, Ar-Ar, 2  ArOMe), 153.37 (d, 4  ArOMe). M/z calcd. C18H23O6 
[M + H]+ 335.1489, found 335.1484. 
 
3,3,4,4,5,5-Hexahydroxybiphenyl (8). 3,3,4,4,5,5-Hexamethoxybiphenyl (7) (865 
mg, 2.58 mmol) was partially dissolved in dry CH2Cl2 (10 mL) and the solution was 
cooled using a dry ice acetone mixture. A solution of BBr3 in CH2Cl2 (1.0 M, 25 mL) 
was added over 5 min to the cooled solution that turned yellow and was allowed to 
warm to ambient temperature over a period of 19 h. An aqueous solution of 1 M HCl 
(50 mL) was added to the cooled mixture (dry ice-acetone) which resulted in a white 
and brick red precipitate. Water (100 mL) was then added and the layers separated. The 
aqueous layer was extracted with ethyl acetate (4 × 100 mL), dried (MgSO4) and the 
solvent was evaporated. The remaining solid was suspended in ether (40 mL) to 
dissolve any of the impurities and filtered to give the title compound (8) as a salmon 
pink-colored solid (609 mg, 94%). 1H NMR (400 MHz, (d6-DMSO) 6.19, 6.35, 6.38 (4 
H, 3 s, 4  ArH), after D2O exch, 6.39 (s, 4  ArH), 7.04 (v br s, 6  OH, ArOH, D2O 
ex), (100 MHz, d6-DMSO) 104.83 (d, 4  Ar-H), 131.38, 132.03, 146.11, 146.19 (s, Ar-
Ar, 6  ArOH). M/z calcd. C12H11O6 [M + H]+ 251.0550, found 251.0540. 
 
3,3,4,4,5,5-Hexakis(diethoxyphosphoryloxy)biphenyl (9). A mixture of diethyl 
chlorophosphite (1.33 mL, 7.8 mmol) and N,N-diisopropylethylamine (1.75 mL, 10.0 
mmol) was stirred at room temperature in dry CH2Cl2 (10 mL) to give a yellow solution. 
3,3,4,4,5,5-Hexahydroxybiphenyl (8) (250 mg, 1 mmol) was added in small portions 
and the solid dissolved with the aid of ultrasound within 5-10 min. The solution 
remained a yellow color and was stirred for a further 30 min. The mixture was cooled 
using dry ice in acetone, mCPBA (2.58 g, 15 mmol) in CH2Cl2 (25 mL) was added in 
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one portion, the color turned a dark olive green and the solution was stirred for a further 
30 min. The mixture was washed with 0.5 M aqueous phosphate buffer pH 7.4 (2 × 100 
mL), dried, and purified by flash chromatography, eluting with EtOAc then EtOAc-
EtOH (5:1) to give the title compound as a pale yellow syrup (780 mg, 80 %), Rf = 0.24 
(EtOAc-EtOH, 5:1). 1H NMR (400 MHz, CDCl3) 1.35-1.41 (m, 36 H, 6  
ArOP(O)(OCH2CH3)2), 4.21-4.38 (m, 24 H, 6  ArOP(O)(OCH2CH3)2). 13C NMR (100 
MHz, CDCl3) 16.03, 16.10 (q, ArOP(O)(OCH2CH3)2), 64.94, 64.99, 65.05 (t, 
ArOP(O)(OCH2CH3)2), 115.53 (d, 4  ArH), 133.03 (app q, Cq, J = 8.1 Hz, ), 136.54 
(s, Cq, Ar-Ar), 143.88 (dd, Cq, J = 3.7, 5.9 Hz, Cq, ArO(O)P(OCH2CH3)2). 
31P (162 
MHz, CDCl3) 4.99 (s, 1P, ArO(O)P(OCH2CH3)2), 5.79 (s, 1P, 
ArO(O)P(OCH2CH3)2), 5.80 (s, 1P, ArO(O)P(OCH2CH3)2). M/z calcd. C36H65O24P6 
[M + H]+ 1067.2286, found 1067.2273. Calcd for C36H64O24P6 C 40.53, H 6.05; found: 
C 40.1, H 6.06. 
 
3,3,4,4,5,5-Biphenylhexakisphosphate (3). 3,3',4,4',5,5'-Hexakis- 
(diethoxyphosphoryloxy)biphenyl (9) (106.6 mg, 100 μmol), was dissolved in dry 
CH2Cl2 (5 mL). Bromotrimethylsilane (1.0 mL, 7.57 mmol) was added and the solution 
was stirred for 3 days after monitoring the disappearance of the ethyl groups from the 
compound. The solvents were evaporated and the remaining syrup was stirred in a 
mixed solvent of TEAB (1 mL) and water (2 mL) for 30 min. The title compound was 
purified over Q-Sepharose Fast Flow using a linear gradient of 0→2.0 M TEAB, eluting 
at 2.0 M buffer and the title compound obtained as a glassy triethylammonium salt 
(90.66 μmol, 91%). Compound 3 was reported surprisingly [19] to stimulate the release 
of intracellular Ca2+, possibly via Ins(1,4,5)P3 receptors or via another mechanism. 
1H 
NMR (400 MHz, D2O) 7.34 (s, 4 H, 4  ArH). 13C NMR (100 MHz, D2O) 114.87 (d, 4 
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 ArH), 134.66 (d, Cq, J = 1.5 Hz, ArO(O)P(OCH2CH3)2), 135.39 (app q, Cq, J = 8.5 
Hz, ArO(O)P(OCH2CH3)2), 145.77 (dd, Cq, J = 3.1, 6.1 Hz, ArO(O)P(OCH2CH3)2). 
31P 
(162 MHz, D2O) 5.82 (s, 6 P, 6  ArOPO32). M/z calcd. C12H15O24P6 [M  H] 
728.8384, found 728.8369. 
 
5-Phosphatase Inhibition Assay. The enzyme activity was monitored based on the 
method previously used [4], that incorporated the established malachite green 
phosphate assay (BioAssay Systems) to measure the inorganic phosphate released by 
the reaction. A typical assay was carried out in a total volume of 50 µL with a buffer 
containing 20 mM HEPES pH 7.5, 5% glycerol, 300 mM NaCl, 2 mM TCEP and 2 mM 
MgCl2. The enzymes, 0.01 µM for INPP5B and 0.1 µM for untagged and His-tagged 
SHIP2, were incubated at 30 °C for 5 min with 50 µM Ins(1,4,5)P3 for INPP5B and 100 
µM Ins(1,3,4,5)P4 for SHIP2. For IC50 determination, serial dilutions of the inhibitors 
were added. The assay was stopped by the addition of 12 µL of 10 % TCA. The free 
phosphate was measured by the addition of 40 µL of malachite green working reagent 
and 98 µL water, followed by incubation at room temperature for 30 mins. The 
absorbance was measured at 620 nm. 
 
Protein Expression and Purification. The sequences encoding INPP5B residues 259-
563 were sub-cloned into the vector pNIC-CH2 adding a C-terminal 6  His-Tag. The 
proteins were expressed in Escherichia coli strain BL21(DE3) R3 pRARE. Cultures 
were grown in TB medium supplemented with 8 g/L glycerol, 100 µg/mL kanamycin 
and 34 µg/mL chloramphenicol in a LEX bioreactor system (Harbinger Biotechnology) 
at 37 C until OD600 reached ~2. The culture temperature was reduced to 18 C over a 
period of 1 h before target expression was induced by addition of 0.5 mM IPTG. 
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Expression was allowed to continue overnight. Cells were harvested by centrifugation 
(4,430  g, 10 min, 4 C) and the pellet was re-suspended in lysis buffer (100 mM 
HEPES, 500 mM NaCl, 10% glycerol, 10 mM imidazole, 0.5 mM TCEP, 2000 U 
Benzonase Merck, Complete EDTA-free protease inhibitor, pH 8.0). Cells were 
disrupted by sonication (Vibra-Cell, Sonics) at 80% amplitude for 3 min effective time 
(pulsed 4s on, 4s off) and cell debris was removed by centrifugation (49,000  g, 20 
min, 4 C). The supernatant was decanted and filtered through a 0.45 µm flask filter. 
The filtered lysate was loaded onto Ni-charged HiTrap Chelating HP (GE Healthcare) 
column and washed with IMAC wash1 buffer (20 mM HEPES, 500 mM NaCl, 10% 
glycerol, 10 mM imidazole, 0.5 mM TCEP, pH 7.5) followed by IMAC wash2 buffer 
(20 mM HEPES, 500 mM NaCl, 10% glycerol, 25 mM imidazole, 0.5 mM TCEP, pH 
7.5). Bound protein was eluted from the IMAC column with IMAC elution buffer (20 
mM HEPES, 500 mM NaCl, 10% glycerol, 500 mM imidazole, 0.5 mM TCEP, pH 7.5) 
and subsequently loaded onto a HiLoad 16/60 Superdex 200 Prep Grade column (GE 
Healthcare) equilibrated in gel filtration buffer (20 mM HEPES, 300 mM NaCl, 10% 
glycerol, 0.5 mM TCEP, pH 7.5). 
 
Stability Studies by Differential Static Light Scattering (DSLS). The effect of 
compounds and substrate/inhibitor analogues on thermal stability of 5-phosphatases 
was studied by Differential Static Light scattering (Stargazer384TM, harbinger). Protein 
samples at 0.2 mg/mL were heated from 25 to 80 C at a rate of 1 C/min in clear bottom 
384-well plates (Nunc) in 50 µL of buffer (20 mM Hepes, 300 mM NaCl, 20% glycerol, 
2 mM MgCl2, 2 mM TCEP, pH 7.5). Protein aggregation was measured by recording 
the scattered light using a CCD camera taking images of the plate every 0.5 C. 
Aggregation temperature was calculated as previously described [21,22]. ΔTagg was 
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calculated as the difference in aggregation temperature between samples with no 
compound added and the sample with addition of 0.5 mM compound. The plot 
(Supporting Information Scheme S1) shows the average ΔTagg values for duplicate 
samples. 
 
Crystallization and Data Collection. Crystallization experiments were performed 
using the sitting-drop method. Prior to setting-up the crystallization trials INPP5B was 
incubated on ice with either 2 mM BiPh(3,3,4,4,5,5)P6 and 2 mM MgSO4 or 2 mM 
Bz(1,2,4,5)P4 and 2 mM MgSO4. Protein concentration used in the crystallization trials 
was 18 and 22 mg/mL, respectively. Crystals were obtained by mixing either 0.2 µL of 
protein solution with 0.1 µL precipitant (complex with BiPh(3,3,4,4,5,5)P6) or 0.1 µL 
of protein solution with 0.2 µL precipitant (complex with Bz(1,2,4,5)P4). The 
precipitant was composed of 10% glycerol, 25% propanediol and 0.1 M 
sodium/potassium phosphate pH 6.2 (BiPh(3,3,4,4,5,5)P6) or of 0.2 M Li2SO4, 0.1 M 
Bis-Tris pH 5.5 and 25% PEG3350 (Bz(1,2,4,5)P4). Crystallization trials were 
incubated at 4 C. Crystals were then harvested, briefly transferred into a cryoprotectant 
solution whose composition was similar to the precipitant supplemented with either 
25% final concentration glycerol and 2 mM MgSO4 (complex with 
BiPh(3,3,4,4,5,5)P6) or 21.7% glycerol, 2 mM MgSO4 and 2 mM Bz(1,2,4,5)P4 
(complex with Bz(1,2,4,5)P4). Crystals were flash-frozen into liquid nitrogen. Data 
were recorded at BESSY light source on beamlines BL14.2 and BL14.1 for complexes 
with BiPh(3,3,4,4,5,5)P6 and Bz(1,2,4,5)P4 respectively. 
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Data Processing, Structure Solution, Model Building and Refinement. Data were 
integrated with XDS [23], scaled with Scala [24,25]. Structures were solved by 
Molecular Replacement with Phaser [26] using the structure of apo-INPP5B (PDB code 
3N9V) as a probe. Model-building and refinement were performed by using iterative 
cycles of manual model building with Coot [27] and maximum-likelihood refinement 
with Refmac 5.5 [24,28] (complex with BiPh(3,3,4,4,5,5)P6) or Buster 2.11 [29] 
(complex with Bz(1,2,4,5)P4). Geometric quality of the final models was assessed using 
Molprobity [30]. Crystallographic statistics are summarized in Table 1. 
 
Table 1 here. 
 
Production of the INPP5B 5-Phosphatase Mechanism. Figure 8A was produced by 
overlaying INPP5BBiPh(3,3,4,4,5,5)P6 and INPP5BdiC8PtdIns4P complex 
structures and an Ins(1,4,5)P3 molecule was then overlayed onto the PtdIns4P. The 
Ins(1,4,5)P3 molecule and the dihedral angles of the 5-phosphate of Ins(1,4,5)P3 were 
rotated so that the 5-phosphate group points into the expected binding site, with the 5-
phosphate in an equivalent orientation to the inorganic phosphate and minimal 
difference between the inositol rings of Ins(1,4,5)P3 and diC8PtdIns4P. Finally, the 5-
phosphate of a second identically-orientated Ins(1,4,5)P3 was replaced with a trigonal 
bipyramidal intermediate with 3 planar oxygen atoms in an equivalent orientation to 
the inorganic phosphate. For each stage of the mechanism the residues and Mg2+ from 
the INPP5BBiPh(3,3,4,4,5,5)P6 complex are shown and the other relevant parts of 
the overlay are added so the starting point adds the water molecule from the INPP5B 
diC8PtdIns4P complex and the Ins(1,4,5)P3. The potential intermediate shows the 
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trigonal bipyramidal-modified Ins(1,4,5)P3, and the final stage shows the release of 
products. 
 
Results 
 
Identification of 5-Phosphatase Ligands Suitable for Structural Studies. Forty, 
predominantly synthetic ligands including inositol polyphosphates, inositol 
phospholipids, benzene- and biphenyl polyphosphates, were screened against eight 
inositol polyphosphate 5-phosphatases using a differential static light scattering method 
in a multiwell-format [15]. The stability of the protein was monitored by following 
temperature-induced protein aggregation using light scattering [15]. The variation of 
the temperature of aggregation (Tagg) for all the compounds screened against the 5-
phosphatases is shown in Supporting Information Scheme S1. The compound names 
and structures are shown in Supporting Information Table S1 and the structures of 
all the compounds used in the crystallization trials are found in the Supporting 
Information Figure S1A, S1B and S1C. The compounds that were considered as hits 
generated a Tagg above 2 C and these were followed up by crystallographic studies. 
Negative controls using dimethylsulfoxide and inositol were used in the assay and did 
not reveal any effect on the stability of the protein. 
 
By applying a 2 C in the Tagg cut-off, we identified 16 potential co-crystallization 
ligands for INPP5B. The highest Tagg were observed when the reaction media 
contained product or substrate analogues (between 11 to 13°C) such as the three lipid 
derivatives, diC8-phosphatidylinositol 4,5-bisphosphate (STO1429), diC8-
phosphatidylinositol 4-phosphate (STO1430) and diC8-phosphatidylinositol 3,4,5-
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trisphosphate (STO927) [6]. Noteworthy is that none of the product or substrate 
analogues lacking a phosphate in position 4 of the inositol group, led to a Tagg 
exceeding the 2 C cut-off. This observation can be related with previous studies that 
revealed that INPP5B is specific to PtdIns(4,5)P2 and PtdIns(3,4,5)P3, but is unable to 
mediate the hydrolysis of PtdIns(5)P and PtdIns(3,5)P2 [10]. Besides substrates and 
product analogues, compounds that led to highest Tagg belonged to the BiPhP series. 
All three BiPhP derivatives (labeled STO1415, STO1416 and STO951 Supporting 
Information, Figure S1A and S1C) have Tagg values in the region of 8-10 C. 
INPP5B co-crystallized in the presence of the biphenyl derivative BiPh(3,3′,4,4′,5,5′)P6 
(STO1415) and the single-ringed ligand, Bz(1,2,4,5)P4 (STO949) leading to the highest 
Tagg in this family of compounds. While crystallization with STO1429 and STO927 
led to structures containing the product of the reaction [6], the aromatic phosphates are 
resistant to hydrolysis when compared to their inositol-containing counterpart. 
 
Surprisingly, Tagg for OCRL was <2 C for inositol phospholipid derivatives, 
suggesting that either binding to the substrate does not generate a high thermal 
stabilization or a low affinity for the product of the reaction (likely produced during the 
course of the assay). However, the most promising ligands for OCRL, ranked according 
to the amplitude of the thermal-shift induced, are the three biphenylpolyphosphates. 
BiPh(2,3′,4,5′,6)P5 (STO951) gave the highest Tagg value ≈ 8 C, with 
BiPh(3,3,4,4,5,5)P6 (STO1415) and BiPh(2,2,4,4,5,5)P6 (STO1416) both having 
Tagg  6 C. Due to the apparent stability of the complex between ligand and protein, 
these BiPhP derivatives may be suitable candidates for crystallization studies than the 
inositol phospholipid derivatives. 
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Structures of the INPP5BBiPh(3,3,4,4,5,5)P6 and INPP5BBz(1,2,4,5)P4 
Complexes. The crystal structure of the BiPh(3,3,4,4,5,5)P6-INPP5B complex 
contains a single molecule of INPP5B in the asymmetric unit with BiPh(3,3,4,4,5,5)P6 
bound in a shallow pocket. The base of the pocket also contains one Mg2+ ion and a 
molecule of inorganic phosphate (Figure 2, panel A). Examination of the bound 
BiPh(3,3,4,4,5,5)P6 reveals multiple interactions between the 3-, 4-, 5-, 4- and 5-
phosphates with side chain amino acids of INPP5B (Figure 3 panel A and Supporting 
Information Figure S2 panel A). Most of the protein-ligand interactions are focused 
around the 3-, 4- and 5-phosphates on one pole of the ligand inserted into the pocket of 
the active site. The aromatic ring of this pole has an edge to face π-π stacking interaction 
with His-404. The 3-phosphate interacts with Lys-380 and Asn-379 (although this is 
longer range, 3.2 Å). The side chain of Lys-380 is located between the 3- and 4-
phosphates of BiPh(3,3,4,4,5,5)P6, although the interactive bond length with the 4-
phosphate is slightly longer 3.2 Å. Additionally to its interaction with Lys-380, the 4-
phosphate also interacts with Glu-303 and forms a longer range interaction with His-
400 (3.2 Å). The 5-phosphate interacts with sidechain hydroxyl of Tyr-502 and has a 
longer range interaction with Arg-518 (3.2 Å). The other pole of the ligand is orientated 
towards one side at the top of the active site pocket. The 5-phosphate interacts with 
Arg-518, and Lys-516 is positioned between, and interacts with, both the 4- and 5-
phosphates. There are additional interactions between phosphates 5-, 3- and 4-
phosphates and three water molecules. The Mg2+ ion and inorganic phosphate are 
positioned between the 4- and 5-phosphates within a network of potential interactions 
from the phosphate groups (Figure 3 panel A). 
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Figure 2 here 
 
In contrast to the BiPh(3,3,4,4,5,5)P6INPP5B structure, the Bz(1,2,4,5)P4INPP5B 
structure (Figure 2 panel B, Figure 3 panel C & D, Supporting Information Figure 
S2 panel B & C) has two molecules of INPP5B in the asymmetric unit. Each molecule 
has one Bz(1,2,4,5)P4 ligand bound in the same shallow pocket as 
BiPh(3,3,4,4,5,5)P6, but lacking both the active site metal ion or inorganic phosphate 
(Figure 2 panel B). An overlay of the two molecules in the asymmetric unit shows a 
shift ca 0.4 Å of the aromatic core of Bz(1,2,4,5)P4, indicating a small variation in the 
position and orientation of the phosphate groups between the two molecules. However, 
for both INPP5B structures (Supporting Information Figure S2 panel B and C) all 
phosphates of Bz(1,2,4,5)P4 produce similar interactions with side chains of INPP5B. 
The only noticeable difference between the two structures involves the 1-phosphate, 
where chain A has a longer range interaction (3.6 Å) with His-404. However, for chain 
B the small shift of Bz(1,2,4,5)P4 allows the 1-phosphate to move away from His-404 
and towards Lys-380, which itself shifts to form a bidentate interaction with the 1-
phosphate. The 2-phosphate interacts with Glu-303, Lys-380 and His-400 sidechains of 
chain A as well as showing longer range interactions with Asn-449 (3.3 Å) and Arg-
451 (3.5 Å). In chain B the shift in Lys-380 means it no longer interacts with the 2-
phosphate, and the longer range interaction with Arg-451 increases to 3.7 Å. The 4-
phosphate shows some variation in rotation between the two molecules, but this 
phosphate still interacts with the same residues (Tyr-502, Lys-503, Lys-516 and Arg-
518), albeit with differences in bond length interactions. The 5-phosphate interacts with 
the side chain of Lys-516 in the asymmetric unit of both INPP5B molecules. In both 
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subunits there is a T-shaped π-π stacking interaction between the aromatic ring of 
Bz(1,2,4,5)P4 and His-404 (Supporting Information Figure S2 panel B and C). The 
aromatic ring also has a π-cation interaction with Arg-451 similar to the complex 
formed between INPP5B and BiPh(3,3,4,4,5,5)P6. There are two equivalent waters in 
each INPP5B molecule with one located between, and interacting with, the 1- and 5-
phosphates of Bz(1,2,4,5)P4 and the other binding to the 2-phosphate (Supporting 
Information Figure S2 panel B and C). There is one extra water molecule in the active 
site of chain A in the asymmetric unit that also interacts with the 2-phosphate. 
 
Figure 3 here. 
 
Unlike other co-structures between 5-phosphatases and ligands, the binding of 
BiPh(3,3,4,4,5,5)P6 and Bz(1,2,4,5)P4 by INPP5B (Figure 3 panel B & D), and also 
that of BiPh(2,3,4,5,6)P5SHIP2 [4] results in additional interactions from a symmetry 
related molecule. Additional interactions with BiPh(3,3,4,4,5,5)P6 and Bz(1,2,4,5)P4 
are mediated by the N-terminal Met-258 and His-tag residues that are carried on the 
INPP5B construct we used for structural studies. There are interactions with the 3-, 3, 
4- and 5'-phosphates of BiPh(3,3,4,4,5,5)P6 and the 1- and 5-phosphates of 
Bz(1,2,4,5)P4. The electron density maps for BiPh(3,3′,4,4′,5,5′)P6 and Bz(1,2,4,5)P4 in 
complex with INPP5B are shown in Supporting Information Figure S3). 
 
Inhibition of INPP5B and SHIP2 by BiPh & BzP Ligands. Inhibition of INPP5B 
activity was measured using a small library of biphenyl and single ring benzene 
polyphosphates to investigate which structural components of BiPh(3,3,4,4,5,5)P6 
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contribute to potent inhibition. Enzyme activity was assayed using the malachite green 
phosphate assay (BioAssay Systems) to measure the release of inorganic phosphate 
from the substrate, A comparison of IC50 values for these inhibitors (Table 2) shows 
the biphenyl polyphosphates are the most potent inhibitors IC50 = 2.4 ± 0.3 µM for 
BiPh(2,3,4,5,6)P5, 5.4 ± 0.7 µM for BiPh(2,2,4,4,5,5)P6 and 5.5 ± 0.5 µM for 
BiPh(3,3,4,4,5,5)P6. Bz(1,2,4,5)P4 was the most potent single ring benzene 
polyphosphate evaluated with an IC50 = 6.3 ± 0.8 µM and only slightly less potent than 
the biphenyl polyphosphate inhibitors. Bz(1,2,3)P3 is the weakest inhibitor, IC50 = 33.5 
± 6.8 µM. It is worth noting that the KM of INPP5B for Ins(1,4,5)P3, previously reported 
using the same malachite green phosphate assay was 55 ± 22 µM [10]. 
 
As described above, the crystal structures of INPP5B with Bz(1,2,4,5)P4 and 
BiPh(3,3,4,4,5,5)P6, as well as the BiPh(2,3,4,5,6)P5SHIP2 complex, all show 
interactions with the His-Tag from a symmetry-related molecule. To investigate the role 
of the His-tag in modulating the interaction with the ligands present in our library, we 
performed a comparative IC50 screen using both His-tag and non-tagged version of 
SHIP2, the sole member of the 5-phosphatases we studied available under a non-tagged 
form. 100 µM Ins(1,3,4,5)P4 was used as the substrate [Ins(1,4,5)P3 is not a substrate 
for SHIP2], with the same range of inhibitors as used with INPP5B, is shown in (Table 
2). The IC50 values for Bz(1,2,3)P3, Bz(1,2,4,5)P4, BiPh(2,3,4,5,6)P5, 
BiPh(2,2,4,4,5,5)P6 and BiPh(3,3,4,4,5,5)P6 with His-Tagged-SHIP2 are >1000, 
108.3±20.3, 28.4±3.8, 19.5±3.1 and 12.3±3.2 µM respectively, and they are >1000, 
69.3±15.4, 24.8±3.0, 15.5±2.5 and 8.4±1.6 µM respectively for untagged-SHIP2. These 
trends show the biphenyl polyphosphate inhibitors to be more potent than the single 
ring benzene polyphosphate compounds, and the most potent biphenyl derivative is 
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BiPh(3,3,4,4,5,5)P6. The results show that the His-Tag has little influence on 
inhibition of SHIP2. Small inhibitory differences are more likely due to small 
intramolecular variations in folding or flexibility caused by the His-Tag, rather than any 
direct intermolecular interactions between the His-Tag and the bound inhibitor. 
 
Table 2 here 
 
DISCUSSION 
 
Further analysis of the crystal structures provide interesting information on two areas 
related to these enzymes. First, comparison of all the 5-phosphatase structures that were 
crystallized as ligand complexes can be used to provide information for the design of 
potent, and specific inhibitors. Second, closer examination of the active site residues, 
metal ions, and the location of the inorganic phosphate ion in the 
BiPh(3,3,4,4,5,5)P6/INPP5B structure, can be used to further elucidate the 
mechanism of these enzymes. 
 
Ligand-Enzyme Structure Comparison. Initial comparison of the two ligand-bound 
INPP5B complexes solved in this study, show there is little change in the overall protein 
structure (rmsd of 0.34 Å for 268 Cα that structurally align). In addition, the overlay 
shows the aromatic core of Bz(1,2,4,5)P4 occupying a similar position as one ring of 
BiPh(3,3,4,4,5,5)P6 that is located near the base of the active site pocket (Figure 4), 
but with some difference in their orientation. This results in the 4- and 5-phosphates of 
BiPh(3,3,4,4,5,5)P6 overlaying well with the 2- and 4-phosphates of Bz(1,2,4,5)P4 
respectively, and sharing many of the same interactions with INPP5B (Figure 3 panel 
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A & C). In the overlay, the 3-phosphate of BiPh(3,3,4,4,5,5)P6 is close to the 1-
phosphate of Bz(1,2,4,5)P4. The change in the orientation of the two ligands is due to 
the position of the cycles between Bz(1,2,4,5)P4 and BiPh(3,3,4,4,5,5)P6 which has 
been rotated by 48° along the axis formed by the carbon 1 and 4 (according to the 
BiPh(3,3,4,4,5,5)P6 numbering) on the ring. The consequence is a displacement of 
phosphorus 3 and 5 of 1.19Å and 1.44Å respectively, when comparing the two 
complexes. The rotation may be caused by interactions of the 1-phosphate of 
Bz(1,2,4,5)P4 with a symmetry related molecule (see above) that does not occur in 
solution, or by a polar interaction between His-404 and the 5-phosphate of 
Bz(1,2,4,5)P4 that stabilizes a conformation where the ligand is more deeply buried in 
the active site. This comparison shows that the two ligands orientate in the active site 
largely in order to maximise interactions with their phosphates at the base of the site. 
 
Figure 4 here 
 
A comparison of these structures with the other structures of INPP5B available (apo, 
diC8-PtdIns4P- and diC8-PtdIns(3,4)P2-bound) revealed that the protein did not undergo 
major conformational changes upon binding the different ligands, with rmsd between 
the different structures in the range of 0.08–0.34 Å where nearly all the Cα structurally 
align (Table 1). The influence of the ligand on the protein structure is only noticeable 
in small differences in the loop region surrounding it. 
 
Two other 5-phosphatase proteins have also been crystallized in complex with ligands, 
namely SHIP2 in complex with BiPh(2,3,4,5,6)P5, and SPsynaptojanin in complex 
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with Ins(1,4)P2. A comparison of all the 5-phosphatase domains in complex with their 
ligands shows that there is little difference in the core structure of the proteins, with at 
least 66% structurally aligning giving rmsd values for these regions all less than 0.77 Å 
(Supporting Information Table S2). The main differences between the different 
proteins are in their external loop regions. 
 
An alignment of all ligand-bound 5-phosphatase structures could give an insight into 
the regions of the enzyme that can be targeted to produce specific, high affinity 
inhibitors for different 5-phosphatases. When all 5-phosphatase/ligand complexes are 
superimposed (Figure 5), the overlay of the ligands show three distinct regions where 
phosphates and/or hydroxyls align well and are likely to be good target areas for 
creating new high affinity inhibitors for all 5-phosphatases. The interactions between 
the ligands and proteins in the six structures are listed in Supporting Information 
Table S3A and S3B. 
 
Common Interactions between Ligand and 5-Phosphatases. The first region where 
a phosphate group is located in all 5-phosphatase/ligand complexes is equivalent to the 
position of the 4-phosphate in PtdIns4P and PtdIns(3,4)P2. In all the structures, the 
phosphorus atom of a phosphate either almost directly superimposes (∆ 0.54 Å for the 
5-phosphate of BiPh(3,3,4,4,5,5)P6 in INPP5B and ∆ 0.76 Å for the 4-phosphate of 
Ins(1,4)P2 in SPsynaptojanin), or is at least close by (∆ 1.11 Å for the 4-phosphate of 
Bz(1,2,4,5)P4 in INPP5B and ∆ 2.6 Å for the 2-phosphate of BiPh(2,3,4,5,6)P5 in 
SHIP2). It is worth noting that the orientation of Ins(1,4)P2 in SPsynaptojanin is very 
different to that of PtdIns4P and PtdIns(3,4)P2 in INPP5B, and that the 5-hydroxyl of 
Ins(1,4)P2 is located some distance from the proposed active site residues. Therefore it 
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is unlikely that this orientation of Ins(1,4)P2 is correct for the substrate binding position 
in SPsynaptojanin and has been discussed previously [6]. As shown in Supporting 
Information Tables S3A and S3B, some residues and interactions are conserved in all 
structures, while some interactions are provided by alternative residues in the different 
structures. Additionally, the only reported examples where a 5-phosphatase showed any 
activity towards a substrate without a 4-phosphate, were SPsynaptojanin and SHIP2 
that dephosphorylated PtdIns(3,5)P2.  
 
The second region is centred around the 1-phosphate of PtdIns4P and PtdIns(3,4)P2, 
that overlays with the 3-phosphate from BiPh(3,3,4,4,5,5)P6 and the 1-phosphate of 
Bz(1,2,4,5)P4 in the INPP5B structures. Although neither the 3- or 5-phosphate of 
BiPh(2,3,4,5,6)P5 from SHIP2 overlay exactly with the 1-phosphate of PtdIns4P, they 
are positioned either side. As with the first region, this site has some conserved 
interactions, but also all the phosphate groups have additional interactions with the 
protein, which indicates this maybe another important region to target for high affinity 
inhibitors.  
 
Finally, in the overlay, the 4-phosphate of BiPh(3,3,4,4,5,5)P6, and the 2-phosphate 
of Bz(1,2,4,5)P4 in the INPP5B complex structures are located in the region between 
the 5- and 6-hydroxyls of PtdIns4P and PtdIns(3,4)P2. Similar to the other two regions, 
this area has some largely conserved, as well as additional specific interactions. 
Therefore these three regions will be good areas to target in order to provide potential 
inhibitors with high affinity, but due to all 5-phosphatases providing many interactions 
in these regions, targeting them is unlikely to give specificity. 
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 A potentially more effective inhibitor could be designed based upon structures similar 
to our aromatic phosphate compounds by extending a phosphate containing one or two 
carbon units, in order to provide a longer reach than the 4-phosphate of 
BiPh(3,3,4,4,5,5)P6. The phosphate group of a new inhibitor should potentially locate 
in the same binding position as the 5-phosphate anion observed in the 
BiPh(3,3,4,4,5,5)P6-INPP5B structure, and increase the number of potential 
interactions from the catalytic residues described below. 
 
Specific Interactions between Ligand and the 5-Phosphatases. Specific inhibitors 
could be designed by considering the interactions that are not conserved in the ligand-
enzyme overlay. Figure 5 shows these are located away from the active site itself. The 
3-phosphate of PtdIns(3,4)P2, the 3-, 4- and 5-phosphates of BiPh(3,3,4,4,5,5)P6, 
and the 5-phosphate of Bz(1,2,4,5)P4, all have additional interactions with INPP5B. 
Likewise the 4- and 6-phosphates of BiPh(2,3,4,5,6)P5, and the 1-phosphate of 
Ins(1,4)P2 have additional interactions with SHIP2 and SPsynaptojanin respectively. 
These phosphates do not overlay with each other, have varied interactions, and are thus 
more likely to be specific. By targeting this region a selective 5-phosphatase inhibitor 
is more likely to be produced. Another potential method to increase inhibitor specificity 
is to target differences in the loop regions at the entrance to the active site. For example, 
the flexible SHIP2 loop (residues 672-684) [4] is elongated compared to equivalent 
loops in INPP5B and SPSynaptojanin. If BiPh(2,3,4,5,6)P5 bound in the same 
orientation as BiPh(3,3,4,4,5,5)P6 in the INPP5B structure, steric clashes would occur 
with the loop. The apex of this loop is flexible and provides potential target for 
designing potent ligands [4]. 
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Figure 5 here 
 
 
Figure 6 here 
 
Implications for the Catalytic Mechanism Model. The catalytic mechanism by which 
the 5-phosphatases hydrolyze their substrate is conserved within the 
apurinic/apyrimidic family of endonucleases (AP-endonucleases). Recently, structures 
of INPP5B bound to product analogues [6] allowed detailed mapping of the catalytic 
residues when compared with mechanistic studies performed using members of the AP-
endonuclease family. While the role of the general base is confirmed as residue Asp-
447, there is still uncertainty as to the number and the location of the participating metal 
ions. The competing models involve either a single-metal, a dual-metal or single 
moving metal mechanism [34]. To date, all metal-bound structures of either 5-
phosphatases or AP-endonucleases show the presence of a single-metal located in the 
so-called A-site. The only structure comprising of two metals has been observed in the 
case of an AP-endonuclease bound to two Pb atoms (one in the A-site, the second in a 
site named B). The size of the atoms and the pH used during the crystallization 
experiments has raised questions about the relevance of this structure and the 
plausibility of a dual-metal mechanism. Molecular dynamics studies have led to the 
hypothesis in which the metal would be first positioned in site B of the moving metal 
mechanism. Here, the metal ion would help to activate the attacking water molecule to 
move to site A where it would help to stabilize the product after the appearance of an 
additional negative charge. The most recent studies based upon alignment with distant 
homologs of AP-endonucleases favors the existence of a single metal in site A which 
helps to stabilize the intermediate and release the product. 
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In the structure of product analogue-bound INPP5B, a metal is present in site A. In an 
OCRL structure an inorganic phosphate present has been attributed a role as an inositol 
5-phosphate mimic. Therefore, superimposition of the OCRL structure with INPP5B 
product bound structures allowed modeling of an intact substrate, and then to identify 
residues involved in the catalysis [6]. Noteworthy, OCRL also contains a metal 
positioned in site A. To aid our understanding of the catalytic mechanism of 5-
phosphatases, we performed a superimposition of these two structures together with the 
structure of INPP5B bound to BiPh(3,3,4,4,5,5)P6 (Figure 7). The inorganic 
phosphate present in the complex with BiPh(3,3,4,4,5,5)P6 appears to be located at 
2.38Å from the phosphate present in the OCRL structure. Moreover, its phosphorus 
centre is located 3.7Å from the 5-hydroxyl present in INPP5B bound to PtdIns(3,4)P2. 
The inorganic phosphate present in the complex with BiPh(3,3,4,4,5,5)P6 is also 
interacting directly with Asp-447 which is expected to be the catalytic base. The 
distance between its phosphorus atom and Asp-447 is only 3.3Å and thus, would not 
allow the catalytic water molecule to be correctly oriented to attack the phosphorus 
atom. Therefore, our structure cannot represent the scissile 5-phosphate of an intact 
substrate due to these distances. 
 
Although Arg-451 is conserved in all members of the 5-phosphatases family, no role 
could be attributed to this residue whether catalytic or substrate-binding. In addition to 
Asp-447, Arg-451 is one of the main coordinating residues to inorganic phosphate in 
the structure of INPP5B-BiPh(3,3,4,4,5,5)P6. Therefore, we believe that the structure 
of INPP5B-BiPh(3,3,4,4,5,5)P6 helps us to pick up an essential intermediate in the 
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catalytic cycle of the 5-phosphatase in which the 5-phosphate is cleaved but is still 
retained in the active site.  
 
Figure 7 here 
 
The mechanism suggested for 5-phosphatases based on the AP endonuclease, proposes 
the activation of a water molecule by Asp-447 (INPP5B numbering), which removes a 
proton forming an attacking nucleophile. In INPP5BPtdIns4P, 
SPsynaptojaninIns(1,4)P2 apo-SPsynaptojanin and SHIP2BiPh(2,3,4,5,6)P5, a 
water molecule close to Asp-447 (or equivalent residue) overlays precisely with one of 
the oxygen atoms of inorganic phosphate in the crystal structure of complex between 
INPP5B and BiPh(3,3,4,4,5,5)P6 (Figure 6 panel B). It is located at 3.6Å from the 
carboxylic moiety of catalytic Asp-447, 3Å from the phosphorus of the inorganic 
phosphate present in OCRL (which has been postulated to mimic the pre-scissile 
position of the 5-phosphate) and is in-line between these two groups. Therefore, it 
appears as a suitable candidate for playing the role of the attacking water molecule 
(Figure 7).  
 
The phosphate in this mechanism will go through a trigonal bipyramidal intermediate 
that will need to be stabilized by interactions with the protein. Direct evidence for such 
an intermediate has been previously observed in the crystal structure of phosphorylated 
β-phosphoglucomutase in the presence of the Mg2+ and either of the substrates glucose 
1-phosphate or glucose 6-phosphate [35,36]. In both structures of the enzyme–Mg2+–
glucose 1,6-bisphosphate complex, there is a stabilized trigonal bipyramidal 
intermediate of the 1-phosphate. Arg-451 is close to one side of the phosphate ion 
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(3.2Å), and is suitably orientated to help stabilize the intermediate. A further possible 
mechanism for the enzymatic hydrolysis of a phosphate monoester by type II inositol 
5-phosphatase [37] could involve a metaphosphate (PO3
˗) intermediate. Evidence from 
other previous experiments for this potential intermediate is derived from 
trifluoromagnesate (MgF3
˗), a metaphosphate surrogate and a discrete transition state 
analogue that has been co-crystallized in the presence of β-phosphoglucomutase 
together with glucose 6-phosphate or α-galactose 1-phosphate and Mg2+. Currently, 
there is no evidence for this metaphosphate involvement in the mechanism of INPP5B, 
but is included for completeness [37] (and references therein). 
 
A comparison between the structure of INPP5B-PtdIns(3,4)P2 and INPP5B-
BiPh(3,3,4,4,5,5)P6 shows that only two residues are subjected to conformational 
changes, these are Asn-273 and fully conserved Glu-303. Both these residues are 
involved in the Mg2+ coordination in the two structures through their side chains. 
Similarly to the position of the inorganic phosphate, the location of the Mg2+ also differs 
in the INPP5B-BiPh(3,3,4,4,5,5)P6 and OCRL structure (by 3.15Å) but is still 
coordinated by the inorganic phosphate in both cases. 
 
Therefore, in order to complete the model previously proposed, we suggest that the 
water molecule previously described would act as the nucleophile after deprotonation 
by Asp-447. The resulting trigonal bipyramidal intermediate would then be stabilized 
by Arg-451 and, after the cleavage of the phosphate monoester, the motion exerted by 
Asn-275 and Glu-303 would transport the Mg2+ and inorganic phosphate away from the 
other reaction product, potentially, also aided by Asn-273. This step is stabilized by the 
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interaction between the released phosphate and conserved residues Arg-451 and Asp-
447 that would then have a dual role during the catalytic cycle (Figure 8A & B). 
 
The structure of INPP5B-BiPh(3,3,4,4,5,5)P6 can be considered as a snapshot in the 
catalytic cycle of 5-phosphatases and provides, together with the other snapshot 
represented by the overlay of INPP5B-diC8-PtdIns(3,4)P2 with the inorganic phosphate 
of OCRL, atomic details about the transformations and conformational changes which 
occur during the reaction catalyzed by 5-phosphatases. 
 
In this case the Mg2+ would move from the site A towards the site B (but not such that 
it reaches it) Figure 8B. Moreover, the region around site B is able to accommodate a 
metal (as suggested by crystallography or molecular dynamics) but the role of this site 
is not to activate the nucleophile but to stabilize the phosphate leaving group and help 
the release of the other product. Here we propose that the metal is moving throughout 
the catalysis but to a smaller extent than previously described in the controversial 
moving-metal mechanism. The structure of INPP5B-BiPhP is thus a key element in 
unifying the different theories developed around the number and the role of the metal 
ions in either 5-phosphatase- or AP-endonuclease-mediated catalysis. 
 
Figure 8A and 8B here 
 
Although both INPP5B and SHIP2 bind biphenyl polyphosphates more strongly than 
the single ring benzene polyphosphate compounds, there are some differences between 
the two proteins. BiPh(2,3,4,5,6)P5 is the most potent inhibitor of INPP5B, although 
only slightly more potent than the other biphenyl compounds, whereas 
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BiPh(3,3,4,4,5,5)P6 is clearly the most potent inhibitor of SHIP2. For single ring 
compounds, Bz(1,2,4,5)P4 is only slightly less potent than the biphenyl inhibitors for 
INPP5B, and Bz(1,2,3)P3 is the weakest INPP5B inhibitor but still in the low 
micromolar range. The single ring ligands have significantly lower affinity for SHIP2 
compared to the biphenyl compounds with Bz(1,2,3)P3 showing very poor inhibition > 
1 mM. 
 
CONCLUSIONS 
 
The inositol 5-phosphatase family of proteins is of pharmacological importance [14]. 
The orally active AQX-1125, a small molecule activator of the 5-phosphatase family 
member SHIP1 is currently in phase 2 trials [38]. The structures of our INPP5B-ligand 
complexes presented here may further aid development of new drug-like compounds 
for this family. 
 
Ligands potentially suitable for this INPP5B 5-phosphatase structural study were 
evaluated using a thermal shift assay and two non-inositol polyphosphate-based 
compounds were selected, resulting in two X-ray co-crystal structures. The high Tagg 
obtained for these compounds suggests that they might be prioritized over inositol 
polyphosphate derivatives, for example for type I 5-phosphatase (INPP5A) or other 
inositol polyphosphate binding proteins whose crystal structure is as yet unavailable. 
These benzene and biphenyl polyphosphates are emerging more generally as useful 
inositol polyphosphate surrogates [4, 17]. Inhibition studies of INPP5B showed that all 
the biphenyl phosphates were more potent than the benzene phosphate derivatives. 
Although interactions between the inhibitors and the protein purification tag were 
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observed in the crystal structures, solution data suggest that ligand binding and 
inhibition is not influenced by this extra sequence. 
 
The mechanism of dephosphorylation by a 5-phosphatase is currently based upon that 
related to an AP endonuclease and postulates that Mg2+, His-400, Asn-449 and His-549 
(INPP5B numbering) should be close to, and interact with, the 5-phosphate from a 
suitable inositol polyphosphate substrate. The structure of the 
BiPh(3,3,4,4,5,5)P6INPP5B complex revealed a molecule of inorganic phosphate 
located close to Asp-447, proposed to activate the attacking water molecule. We 
propose that this inorganic phosphate occupies the location of the cleaved 5-phosphate 
after substrate hydrolysis by the enzyme. Interestingly, in our structure Arg-451 
(conserved throughout the 5-phosphatase family) is located close to the inorganic 
phosphate, suggesting that it plays a role in the 5-phosphatase mechanism, although not 
previously identified as such. Arg-451 may help to stabilize the pentacoordinate 
intermediate and facilitate the hydrolysis of the 5-phosphate by aiding its release from 
the substrate. From our structure and the overlays in Figure 8, the identification of both 
Arg-451 and a candidate water molecule for the first step of the hydrolysis reaction 
refines the catalytic mechanism for INPP5B 5-phosphatase, and with implications for 
the “moving metal” mechanism, but still broadly in line with that generally proposed 
for the 5-phosphatase family. 
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Table 1. Data collection and refinement statistics 
 INPP5B 
 BiPh(3,3,4,4,5,5)P6 Bz(1,2,4,5)P4 
PDB Id 5A7I 5A7J 
Data collection   
Synchrotron Bessy  Bessy 
Beamline BL14.1 BL14.1 
Wavelength (Å) 0.91841 0.91841 
Resolution range (Å) 34.29-2.89 48.48-2.90 
(outest shell) (3.05-2.89) (3.06-2.9) 
Space group P41212 P21 
Unit-cell dimensions (Å) a = 96.97 a = 52.26 
 b = 96.97 b = 94.44 
 c = 152.14 c = 78.31 
Unit-cell angles (◦) α=β=γ=90 α=γ=90, β=106.32 
Completeness (%) 99.9 (100.0) 99.7 (99.7) 
Unique reflections 16922 16223 
Mean (I)/sd(I)a 21.2 (2.2) 6.9 (2.3) 
Redundancy 7.0 (7.2) 3.6 (3.6) 
Rmeas (%)
b 7.5 (90.7) 19.4 (67.9) 
Refinement   
Resolution range (Å) 34.29-2.89 48.48-2.90 
(outest shell) (2.97-2.89) (3.10-2.90) 
Rcryst (%)
c 19.8 (33.8) 20.2 (21.9) 
Rfree (%)
d 22.3 (34.5) 25.0 (31.0) 
Model content   
 43 
       Protein atoms 2545 4971 
       Ligand atoms 42 52 
       Metal atoms 1 0 
       Water molecules 28 76 
       Others 16 26 
Average B factors (Å2)   
       Protein atoms 83.59 39.10 
       Ligand atoms 76.44 65.84 
       Metal atoms 66.37 n.d. 
       Water molecules 71.94 19.15 
       Other atoms 111.59 63.89 
R.m.s.d. bonds (Å) 0.007 0.008 
R.m.s.d. angles (◦) 1.191 1.000 
Ramachandran plot (%)e   
(favored, outliers) 95.82, 0.32 94.95, 0 
 
 
 
 
aMean (I)/sd is the mean ratio for all reflections of <Ih>/sd<Ih> where, for each 
unique reflection h, <Ih> is the weighted mean of  measured Ih and sd<Ih> is the 
mean of estimated error sd(I). 
 
b Rmeas =  
 
c Rcryst =                                                         where Fobs and Fcalc are the observed 
and calculated structure factors respectively. 
dRfree is the same as Rcryst but based on a subset of 5% (5.1% and 5.0% for INPP5B-
BiPh(3,3,4,4,5,5)P6 and INPP5B-Bz(1,2,4,5)P4, respectively) of reflections 
omitted during refinement. 
eValues computed by Molprobity (reference 26). 
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Table 2 
 IC50 (µM) 
 His-Tag-INPP5B SHIP2 (no tag) His-Tag-SHIP2 
Bz(1,2,3)P3 33.5 ± 6.8 >1000 >1000 
Bz(1,2,4,5)P4 6.3 ± 0.8 69.3 ± 15.4 108.3 ± 20.3 
BiPh(2,3,4,5,6)P5 2.4 ± 0.3 24.8 ± 3.0 28.4 ± 3.8 
BiPh(2,2,4,4,5,5)P6 5.4 ± 0.7 15.5 ± 2.5 19.5 ± 3.1 
BiPh(3,3,4,4,5,5)P6 5.5 ± 0.5 8.4 ±1.6 12.3 ± 3.2 
 
Table 2. IC50 Values of a series of compounds for His-Tagged-INNPP5B (0.01 µM 
enzyme, 50 µM Ins(1,4,5)P3), compared to untagged- and His-Tagged-SHIP2 (0.1 µM 
enzymes, 100 µM Ins(1,3,4,5)P4). 
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The synthesis of biphenyl 3,3,4,4,5,5-hexakisphosphate (3). 
Scheme 1: (i) K2CO3, (2 eq), 35°C, acetone/water (3:3.5), 0.5% Pd(OAc)2, 67%; (ii) 
BBr3, CH2Cl2, dry ice/acetone cooling, 94%; (iii) (EtO)2P-Cl, CH2Cl2, 
Diisopropylethylamine, mCPBA (80%); (iv) TMSBr, CH2Cl2, H2O, TEAB (91%). 
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Figure 1 Structures of YU142670 (1), D-myo-inositol 1,3,4,5-tetrakisphosphate (2), 
biphenyl 3,3,4,4,5,5-hexakisphosphate (3) and benzene 1,2,4,5-tetrakisphosphate (4). 
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Figure 2. Cartoon representation of the crystal structure of 
INPP5BBiPh(3,3,4,4,5,5)P6 (panel A) and INPP5BBz(1,2,4,5)P4 (panel B) 
complexes. BiPh(3,3,4,4,5,5)P6, inorganic phosphate and Bz(1,2,4,5)P4 are shown as 
sticks, the Mg2+ ion is shown as a green sphere, β-sheets are in yellow, α-helices in red 
and loop regions in green. For both complexes, the symmetry related molecule that 
provides additional interactions to the phosphorylated ligand is shown in cyan with the 
His-Tag highlighted in dark blue. Only chain A of the INPP5BBz(1,2,4,5)P4 complex 
is shown for clarity. 
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Figure 3. Panel A shows BiPh(3,3,4,4,5,5)P6 bound in the catalytic site of INPP5B, 
with a molecule of inorganic phosphate positioned between the 3- and 4-phosphates. 
The green sphere is a magnesium ion (Mg2+) and the red spheres are water molecules 
in the absence of the His-Tag. Panel B shows the BiPh(3,3,4,4,5,5)P6 bound in the 
catalytic site of INPP5B, in complex with the His-Tag. The carbon atoms of the two 
INPP5B molecules interacting with BiPh(3,3,4,4,5,5)P6 are colored gray (catalytic 
site) and green (neighbouring INPP5B molecule). Panel C shows Bz(1,2,4,5)P4 bound 
in the catalytic site of INPP5B. The red sphere indicates the presence of a molecule of 
water and in the absence of the His-Tag. Panel D shows the presence of Bz(1,2,4,5)P4 
in the catalytic site of INPP5B (carbon atoms colored in gray) bound to the His-Tag of 
a neighbouring INPP5B molecule (carbon atoms are colored yellow). 
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Figure 4 Overlay of Bz(1,2,4,5)P4-INPP5B (green) and BiPh(3,3,4,4,5,5)P6-INPP5B 
(blue) complex structures showing good overlay between the two molecules and 
different phosphate groups. The Mg2+ (blue sphere) and inorganic phosphate (sticks) 
from the BiPh(3,3,4,4,5,5)P6-INPP5B structure are shown, and the numbering of the 
ligand phosphates are included. 
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Figure 5 Overlay of the INPP5B–BiPh(3,3,4,4,5,5)P6 crystal structure with the 
ligands from the other 5-phosphatase-ligand crystal structures (PtdIns4P, PtdIns(3,4)P2 
and Bz(1,2,4,5)P4 from INPP5B complexes, SHIP2BiPh(2,3,4,5,6)P5 and 
SPsynaptojanin–Ins(1,4)P2) highlighting the similarities and differences in the 
phosphate and hydroxyl positions. The 1-phosphate region is shown in blue, the 5- and 
6-hydroxyl region in green and the 4-phosphate region in red. Other phosphates that 
show a variety of different interactions with the protein are shown in yellow. The Mg2+ 
ion is shown as a green sphere and the inorganic phosphate as sticks. 
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Figure 6 (A) Overlay of the proposed catalytic residues for INPP5B–
BiPh(3,3,4,4,5,5)P6 (green), INPP5B–Bz(1,2,4,5)P4 (yellow), INPP5BPtdIns4P 
(dark blue) SHIP2BiPh(2,3,4,5,6)P5 (light blue) and SPsynaptojanin–Ins(1,4)P2 (red) 
complexes. Numbering is for the INPP5B enzyme. (B) Overlay of inorganic phosphate 
from INPP5B–BiPh(3,3,4,4,5,5)P6 complex structure with water molecules from 
INPP5BPtdIns4P, SPsynaptojanin-Ins(1,4)P2 apo-SPsynaptojanin and 
SHIP2BiPh(2,3,4,5,6)P5 structures. Only the catalytic residues surrounding the water 
molecule are shown for clarity. The Mg2+ from INPP5B–BiPh(3,3,4,4,5,5)P6 complex 
structure is shown as a green sphere and the PtdIns4P from the INPP5B complex is 
shown in blue. (C) Overlay of the phosphate anion and co-ordinating residues from the 
INPP5BBiPh(3,3,4,4,5,5)P6 complex with the ligand and the INPP5BPtdIns4P 
complex. (D) Overlay of the active site regions of INPP5B–BiPh(3,3,4,4,5,5)P6 (gray 
carbons; Mg2+ as a green sphere; inorganic phosphate in green) AP endonuclease-DNA 
(pink carbons; Mn2+ as a purple sphere; DNA shown as a cartoon with the cleaved 
sugar-phosphate groups shown as sticks). Residue numbering is for INPP5B with AP 
endonuclease in parenthesis. 
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Figure 7. Superposition of INPP5B-BiPh(3,3,4,4,5,5)P6 (yellow), INPP5B-
PtdIns(3,4)P2 (magenta) and OCRL (cyan). Amino-acids whose side-chains are shown 
as sticks are labeled using the same colour as the protein they correspond. 
BiPh(3,3,4,4,5,5)P6 (yellow) and PtdIns(3,4)P2 (magenta) are represented as thin 
sticks. Mg2+ ions and the putative catalytic water molecule are displayed as spheres. 
Protein-metal, protein-water or protein-phosphate interactions are represented by 
dashes. Spheres and dashes are both coloured yellow, magenta or cyan whether they 
belong to INPP5B-BiPh(3,3,4,4,5,5)P6, INPP5B-PtdIns(3,4)P2 or OCRL structures, 
respectively. The water molecule (present in the structure of INPP5B-diC8-
PtdIns(3,4)P2) that attacks the 5-phosphate upon deprotonation in the mechanism we 
propose is depicted by a red sphere, labelled with a “W”. Free phosphates are labeled 
using either a yellow or a cyan font whether they were present in INPP5B-
BiPh(3,3,4,4,5,5)P6 or OCRL structure. 
 
  
 53 
 
A                                                              B 
 54 
 
Figure 8 (A) Stick diagram showing participants in a pentacoordinate intermediate 
based on the AP endonuclease mechanism. After nucleophilic attack of an activated 
water molecule the trigonal bipyramidal intermediate is stabilized by a series of residues 
and the active site Mg2+ ion. Arg-451 (colored green) was not originally suggested as 
part of the mechanism, but is located such that it may help stabilize the intermediate 
and is conserved in all 5-phosphatases. Only schematic involvement of the various 
residues is depicted. 
 
(B) Mechanism for the hydrolysis of the 5-phosphate of Ins(1,4,5)P3 by INPP5B, based 
upon the stick diagram and interactions found in (A) together with additional 
contributing amino acid residues and the movement of the Mg2+ ion from site A towards 
site B. Attack by a water molecule produces a trigonal bipyramidal intermediate that 
collapses releasing the phosphate anion. The amino acids are color-coded for easier 
recognition. The anion that forms at the 5-position is probably quenched with a proton 
originating from a nearby water molecule, possibly Mg2+-bound, or from the adjacent 
protonated 4-phosphate group. This has not been shown on the diagram for the sake of 
clarity. Key: R = H for Ins(1,4,5)P3, R = diacylglycerol for PtdIns(4,5)P2. Only 
schematic involvement of the various residues is depicted. 
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